Since the FDA approvals of the first PD-1 inhibitors pembrolizumab and nivolumab in 2014, the clinical development of PD-1/PD-L1 inhibitors as a form of cancer immunotherapy has seen unprecedented growth. This evidence concerns the gene PDCD1 and cancer.